



## Declaration on compliance with the ENCePP Code of Conduct for ENCePP Seal studies<sup>1</sup>

The (primary) lead investigator and a person authorised to sign on behalf of the coordinating study entity hereby declare for the purpose of conducting the study <include here study name and identifier/reg.no.>

DUS to Evaluate the Effectiveness of aRMM for Upadacitinib in the Treatment of AD, EUPAS49233

- to follow the rules and principles for the independent and transparent conduct of pharmacoepidemiological and pharmacovigilance studies of the current version of the ENCePP Code of Conduct<sup>2</sup>;
- to inform the ENCePP Secretariat, without delay, of any change or decision to change that constitutes a deviation from the provisions of this Code.

It is of note that the (primary) lead investigator and the person authorised to sign on behalf of the coordinating study entity may be identical.

Name of (primary) lead investigator:

Johan Reutfors

Date: 27/10/2022 (dd/mm/yyyy)

Stamp (if applicable) and signature:

*Johan Reutfors*

Name of the coordinating study entity:

Centre for Pharmacoepidemiology, Karolinska Institutet

Address:

Karolinska Institutet  
Centre for Pharmacoepidemiology  
Karolinska University Hospital T2  
171 76 Stockholm  
Sweden

Name of person authorised to sign on behalf of the coordinating study entity [if different from (primary) lead investigator]:

Date: (dd/mm/yyyy)

Stamp (if applicable) and signature:

The (primary) lead investigator should also complete, sign and date the Checklist of the ENCePP Code of Conduct for ENCePP Seal studies.

<sup>1</sup> Complete the declaration on screen, then print, stamp (if applicable) and sign.

<sup>2</sup> Adopted Code and any revision thereof at the time of signature of the declaration.

Reset Form